Classification of follicular cell-derived thyroid cancer by global RNA profiling

Journal of Molecular Endocrinology

Volumn 50, Issue 2, 2013, Pages

  Rossing, Maria ^a,b  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer; Classification; Global RNA profiling; Thyroid

Indexed keywords

CAVEOLIN 1; CAVEOLIN 2; GLYPICAN 3; GROWTH DIFFERENTIATION FACTOR 10; MICRORNA; SOMATOMEDIN BINDING PROTEIN 6; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

CANCER CLASSIFICATION; DOWN REGULATION; EXTRACELLULAR MATRIX; FOLLICULAR CELL DERIVED THYROID CANCER; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID CANCER;

ADENOCARCINOMA, FOLLICULAR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RNA;

EID: 84875306130     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-12-0170     Document Type: Review

References (69)

1. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C et al. 2003 Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Research 63 2864-2871.
2. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A & Eng C 2004 Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. Journal of Clinical Oncology 22 3531-3539. (doi:10.1200/JCO.2004.08.127)
3. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ et al. 2012 Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. New England Journal of Medicine 367 705-715. (doi:10.1056/ NEJMoa1203208)
4. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA & Fahey TJ III 2003 Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clinical Cancer Research 9 1792-1800.
5. Bartel DP 2004 MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 281-297. (doi:10.1016/S0092-8674(04)00045-5)
6. Bartel DP 2009 MicroRNAs: target recognition and regulatory functions. Cell 136 215-233. (doi:10.1016/j.cell.2009.01.002)
7. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S & Bullerdiek J 2008 Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes, Chromosomes & Cancer 47 56-63. (doi:10.1002/gcc.20505)
8. Bhattacharya A, Ziebarth JD & Cui Y 2013 SomamiR: a database for somatic mutations impacting microRNA function in cancer. Nucleic Acids Research 41 D977-D982. (doi:10.1093/nar/gks1138)
9. Borup R, Rossing M, Henao R, Yamamoto Y, Krogdahl A, Godballe C, Winther O, Kiss K, Christensen L, Hogdall E et al. 2010 Molecular signatures of thyroid follicular neoplasia. Endocrine-Related Cancer 17 691-708. (doi:10.1677/ERC-09-0288)
10. Braun J, Hoang-Vu C, Dralle H & Huttelmaier S 2010 Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene 29 4237-4244. (doi:10.1038/onc.2010.169)
11. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, Clayman GL & El-Naggar AK 2004 Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clinical Cancer Research 10 6586-6597. (doi:10.1158/1078-0432.CCR-04-0053)
12. Chudova D, Wilde JI, Wang ET, Wang H, Rabbee N, Egidio CM, Reynolds J, Tom E, Pagan M, Rigl CT et al. 2010 Molecular classification of thyroid nodules using high-dimensionality genomic data. Journal of Clinical Endocrinology and Metabolism 95 5296-5304. (doi:10.1210/jc.2010-1087)
13. de la Chapelle A & Jazdzewski K 2011 MicroRNAs in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 96 3326-3336. (doi:10.1210/jc.2011-1004)
14. Eszlinger M, Krohn K, Berger K, Lauter J, Kropf S, Beck M, Fuhrer D & Paschke R 2005 Gene expression analysis reveals evidence for increased expression of cell cycle-associated genes and Gq-protein-protein kinase C signaling in cold thyroid nodules. Journal of Clinical Endocrinology and Metabolism 90 1163-1170. (doi:10.1210/jc.2004-1242)
15. Eszlinger M, Wiench M, Jarzab B, Krohn K, Beck M, Lauter J, Gubala E, Fujarewicz K, Swierniak A & Paschke R 2006 Meta- and reanalysis of gene expression profiles of hot and cold thyroid nodules and papillary thyroid carcinoma for gene groups. Journal of Clinical Endocrinology and Metabolism 91 1934-1942. (doi:10.1210/jc.2005-1620)
16. Eszlinger M, Krohn K, Hauptmann S, Dralle H, Giordano TJ & Paschke R 2008 Perspectives for improved and more accurate classification of thyroid epithelial tumors. Journal of Clinical Endocrinology and Metabolism 93 3286-3294. (doi:10.1210/jc.2008-0201)
17. Faquin WC 2008 The thyroid gland: recurring problems in histologic and cytologic evaluation. Archives of Pathology & Laboratory Medicine 132 622-632.
18. Filicori F, Keutgen XM, Buitrago D, AlDailami H, Crowley M, Fahey TJ III & Zarnegar R 2011 Risk stratification of indeterminate thyroid fine-needle aspiration biopsy specimens based on mutation analysis. Surgery 150 1085-1091.
19. Finley DJ, Arora N, Zhu B, Gallagher L & Fahey TJ III 2004a Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. Journal of Clinical Endocrinology and Metabolism 89 3214-3223. (doi:10.1210/jc.2003-031811)
20. Finley DJ, Zhu B, Barden CB & Fahey TJ III 2004b Discrimination of benign and malignant thyroid nodules by molecular profiling. Annals of Surgery 240 425-436. (doi:10.1097/01.sla.0000137128.64978.bc)
21. Finley DJ, Lubitz CC, Wei C, Zhu B & Fahey TJ III 2005 Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. Thyroid 15 562-568. (doi:10.1089/thy.2005.15.562)
22. Franc B, de la Salmoniére P, Lange F, Hoang C, Louvel A, de Roquancourt A, Vilde F, Hejblum G, Chevret S & Chastang C 2003 Interobserver and intraobserver reproducibility in the histopathology offollicular thyroid carcinoma. Human Pathology 34 1092-1100. (doi:10.1016/S0046-8177(03)00403-9)
23. Friedman RC, Farh KK, Burge CB & Bartel DP 2009 Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 19 92-105. doi:10.1101/gr.082701.108)
24. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA & Farace MG 2007miR-221andmiR-222expressionaffectstheproliferationpotentialof human prostate carcinoma cell lines by targeting p27Kip1. Journal of Biological Chemistry 282 23716-23724. (doi:10.1074/jbc.M701805200)
25. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L & Vitti P 2010 American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for clinical practice for the diagnosis and management of thyroid nodules. Journal of Endocrinological Investigation 33 1-50.
26. Gupta RK, Rosen ED & Spiegelman BM 2011 identifying novel transcrip-tional components controlling energy metabolism. Cell Metabolism 14 739-745. (doi:10.1016/j.cmet.2011.11.007)
27. Hawthorn L, Stein L, Varma R, Wiseman S, Loree T & Tan D 2004 TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head & Neck 26 1069-1083. (doi:10.1002/hed.20099)
28. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C et al. 2001 Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. PNAS 98 15044-15049. (doi:10.1073/pnas.251547398)
29. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D et al. 2005 Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Research 65 1587-1597. (doi:10.1158/0008-5472.CAN-04-3078)
30. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, Stadler PF, Hertel J, Hackermuller J, Hofacker IL et al. 2007 RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 316 1484-1488. (doi:10.1126/science.1138341)
31. Kebebew E, Greenspan FS, Clark OH, Woeber KA & McMillan A 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103 1330-1335. (doi:10.1002/cncr.20936)
32. Kim JW & Dang CV 2006 Cancer's molecularsweet toothand theWarburg effect. Cancer Research 66 8927-8930. (doi:10.1158/0008-5472.CAN-06-1501)
33. Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, Zeiger MA & Kebebew E 2012 Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid 22 285-291. (doi:10.1089/thy.2011.0313)
34. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306. (doi:10.1038/nrc1836)
35. Leethanakul C, Patel V, Gillespie J, Pallente M, Ensley JF, Koontongkaew S, Liotta LA, Emmert-Buck M & Gutkind JS 2000 Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. Oncogene 19 3220-3224. (doi:10.1038/sj.onc.1203703)
36. Li H, Robinson KA, Anton B, Saldanha IJ & Ladenson PW 2011 Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. Journal of Clinical Endocrinology and Metabolism 96 E1719-E1726. (doi:10.1210/jc.2011-0459)
37. Lu C, Mishra A, Zhu YJ, Meltzer P & Cheng SY 2011 Genomic profiling of genes contributing to metastasis in a mouse model of thyroid follicular carcinoma. American Journal of Cancer Research 1 1-13.
38. Mazeh H, Mizrahi I, Halle D, Ilyayev N, Stojadinovic A, Trink B, Mitrani-Rosenbaum S, Roistacher M, Ariel I, Eid A et al. 2011 Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid 21 111-118. (doi:10.1089/thy.2010.0356)
39. Montero-Conde C, Martin-Campos JM, Lerma E, Gimenez G, Martinez-Guitarte JL, Combalia N, Montaner D, Matias-Guiu X, Dopazo J, de Leiva A et al. 2008 Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 27 1554-1561. (doi:10.1038/sj.onc. 1210792)
40. Moses W, Weng J, Sansano I, Peng M, Khanafshar E, Ljung BM, Duh QY, Clark OH & Kebebew E 2010 Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World Journal of Surgery 34 2589-2594. (doi:10.1007/s00268-010-0720-0)
41. Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J & Conneely OM 2007 Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nature Medicine 13 730-735. (doi:10.1038/nm1579)
42. Nikiforov YE 2011 Molecular analysis of thyroid tumors. Modern Pathology 24 (Suppl 2) S34-S43. (doi:10.1038/modpathol.2010.167)
43. Nikiforov YE & Nikiforova MN 2011 Molecular genetics and diagnosis of thyroid cancer. Nature Reviews. Endocrinology 7 569-580. (doi:10.1038/ nrendo.2011.142)
44. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, Lebeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT et al. 2011 Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. Journal of Clinical Endocrinology and Metabolism 96 3390-3397. (doi:10.1210/jc.2011-1469)
45. Nikiforova MN, Tseng GC, Steward D, Diorio D & Nikiforov YE 2008 MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. Journal of Clinical Endocrinology and Metabolism 93 1600-1608. (doi:10.1210/jc.2007-2696)
46. Ohori NP, Nikiforova MN, Schoedel KE, Lebeau SO, Hodak SP, Seethala RR, Carty SE, Ogilvie JB, YipL&NikiforovYE2010 Contributionofmolecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathology 118 17-23. (doi:10.1002/cncy.20063)
47. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL & Pritchard KI 2009 Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. Journal of the National Cancer Institute 101 644-650. (doi:10.1093/jnci/djp067)
48. Onda M, Emi M, Yoshida A, Miyamoto S, Akaishi J, Asaka S, Mizutani K, Shimizu K, Nagahama M, Ito K et al. 2004 Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA micro-array of 25 344 genes. Endocrine-Related Cancer 11 843-854. (doi:10.1677/erc.1.00818)
49. Ozsolak F & Milos PM 2011 RNA sequencing: advances, challenges and opportunities. Nature Reviews. Genetics 12 87-98. (doi:10.1038/nrg2934)
50. Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB et al. 2008 Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clinical Cancer Research 14 3327-3337. (doi:10.1158/1078-0432.CCR-07-4495)
51. Prasad NB, Kowalski J, Tsai HL, Talbot K, Somervell H, Kouniavsky G, Wang Y, Dackiw AP, Westra WH, Clark DP et al. 2012 Three-gene molecular diagnostic model for thyroid cancer. Thyroid 22 275-284. (doi:10.1089/thy.2011.0169)
52. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F & Dhesy-Thind B 2008 HER-2 and topoisomerase II as predictors of response to chemotherapy. Journal of Clinical Oncology 26 736-744. (doi:10.1200/JCO.2007.15.4716)
53. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A et al. 2008 MicroRNAs accurately identify cancer tissue origin. Nature Biotechnology 26 462-469. (doi:10.1038/nbt1392)
54. Rossing M, Borup R, Henao R, Winther O, Vikesaa J, Niazi O, Godballe C, Krogdahl A, Glud M, Hjort-Sorensen C et al. 2012 Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma. Journal of Molecular Endocrinology 48 11-23. (doi:10.1530/ JME-11-0039)
55. Schmittgen TD 2008 Regulation of microRNA processing in development, differentiation and cancer. Journal of Cellular and Molecular Medicine 12 1811-1819. (doi:10.1111/j.1582-4934.2008.00483.x)
56. Shen R, Liyanarachchi S, Li W, Wakely PE Jr, Saji M, Huang J, Nagy R, Farrell T, Ringel MD, de la Chapelle A et al. 2012 MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases. Thyroid 22 9-16. (doi:10.1089/thy.2011.0081)
57. Simon R 2003 Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. British Journal of Cancer 89 1599-1604. (doi:10.1038/sj.bjc.6601326)
58. Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru A & Yamashita S 2008 Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Science 99 1147-1154. (doi:10.1111/j.1349-7006.2008.00800.x)
59. Vierlinger K, Mansfeld MH, Koperek O, Nohammer C, Kaserer K & Leisch F 2011 Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Medical Genomics 4 30. (doi:10.1186/1755-8794-4-30)
60. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E et al. 2007a Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26 7590-7595. (doi:10.1038/sj.onc.1210564)
61. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM et al. 2007b MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocrine-Related Cancer 14 791-798. (doi:10.1677/ERC-07-0129)
62. Vizioli MG, Sensi M, Miranda C, Cleris L, Formelli F, Anania MC, Pierotti MA & Greco A 2010 IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene 29 3835-3844. (doi:10.1038/onc.2010.136)
63. Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY, Clark OH & Kebebew E 2012 MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer 118 3426-3432. (doi:10.1002/cncr.26587)
64. Walsh PS, Wilde JI, Tom EY, Reynolds JD, Chen DC, Chudova DI, Pagan M, Pankratz DG, Wong M, Veitch J et al. 2012 Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules. Journal of Clinical Endocrinology and Metabolism 97 E2297-E2306. (doi:10.1210/jc.2012-1923)
65. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, Schuppert F, Broelsch CE, Ringel MD & Eng C 2005 Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. Journal of Clinical Endocrinology and Metabolism 90 2512-2521. (doi:10.1210/jc.2004-2028)
66. Weber F, Teresi RE, Broelsch CE, Frilling A & Eng C 2006 A limited set of human microRNA is deregulated in follicular thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 91 3584-3591. (doi:10.1210/jc.2006-0693)
67. Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD Jr, Kim BW, Nose V, Marqusee E et al. 2007 Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 111 508-516. (doi:10.1002/cncr.23116)
68. Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, Zhang Y, Huang K, Li Y, Song E et al. 2012 Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 97 2084-2092. (doi:10.1210/jc.2011-3059)
69. Zhao J, Leonard C, Brunner E, Gemsenjager E, Heitz PU & Odermatt B 2006 Molecular characterization of well-differentiated human thyroid carcinomas by cDNA arrays. International Journal of Oncology 29 1041-1051.